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ABSTRACT  
Objective: Duloxetine, a selective serotonin and noradrenaline reuptake inhibitor used in major depressive disorders, urinary incontinence and 
diabetic peripheral neuropathic pain. It is reported to be associated with several types of liver injuries, including hepatocellular, cholestatic and 
mixed hepatocellular-cholestatic patterns. The objective of this study was to assess the effect of duloxetine or its metabolites on oxidative stress-
induced liver damages.  
Methods: In this study, animals were divided into five groups. In the first group, the only vehicle was given orally for 21 d. The second group has 
been considered as hepatotoxic control group where Erythromycin was given orally for 14 d and remaining three groups have been considered as 
test groups where duloxetine, fluvoxamine and duloxetine along with fluvoxamine were administered orally for 21 d. Liver GSH, oxidised lipid 
malonaldehyde (MDA), superoxide dismutase (SOD), catalase (CAT), protein carbonyl (PC) and plasma alanine transaminase (ALT), aspartate 
transaminase (AST) and alkaline phosphatase (ALP) levels were measured to determine the level of hepatotoxicity. Scanning electron microscopy 
(SEM) study of liver tissues was also performed to examine the liver injuries.  
Results: GSH and SOD levels were found to be decreased in duloxetine-treated groups with respect to the hepatotoxic control group, whereas 
increased level of MDA, CAT and PC signify the damages of liver cells. Increased level of plasma ALT, AST and ALP at the same time indicated liver 
tissue damage. Opposite effects were observed in the case of duloxetine and fluvoxamine-treated groups. SEM of liver tissues revealed that the 
tissue injury occurred in Duloxetin treated groups, whereas the restoration of normal tissue architecture took place due to the administration of 
duloxetine and fluvoxamine-treated groups.  
Conclusion: Our results collectively indicated that hydroxylated and epoxide metabolites of duloxetine might have hepatotoxic potential due to 
oxidative stress produced by the release of free radicals or reactive oxygen species. 
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Duloxetine (DLX, fig. 1A) [N-methyl-γ-(1-naphthyloxy)-2-thiophene-
propylamine] is a selective serotonin and noradrenaline reuptake 
inhibitor, approved by the USFDA for the treatment of major 
depressive disorders. In addition, it is also used in stress-induced 
urinary incontinence and diabetic peripheral neuropathic pain [1]. 
DLX is highly bind to plasma proteins (>90%) and mainly metabolised 
by various cytochrome (CYP) enzymes, such as CYP1A2 and CYP2D6 
in humans. Although, the naphthyl ring underwent epoxidation and 
subsequently formed adduct with glutathione (GSH), but thiophene 
moiety showed inert after bioactivation [1]. The bioactivation of 
naphthyl ring mediated through CYP1A2 enzyme corresponds to 4-
hydroxy DLX, 6-hydroxy-5-methoxy DLX and 4, 6-dihydroxy DLX [4]. 
Sometimes, naphthyl ring could generate reactive metabolites, i.e. 
epoxides which may cause hepatotoxicity [2]. The role of the CYP2D6 
enzyme during bioactivation of DLX was not prominent in the case of 
both rats and humans.  
 
Fig. 1: Structures of (A) DLX and (B) FLX 
Recently, it has been reported that DLX was reported to be 
associated with several cases of hepatocellular, cholestatic and 
mixed hepatocellular-cholestatic patterns of liver injuries [3]. 
Hepatobiliary diseases were estimated to occur in about 8 per 
100,000 cases, while elevation of enzyme level increased thrice the 
value of normal range as observed in 0.9 to 1.7% of DLX treated 
subjects [4, 5]. Idiosyncratic liver damages were estimated to occur 
about 1-2 per 100,000 cases of exposure in DLX [4]. In a pooled 
analysis of 17615 subjects, the incidence of serum ALT level was 
increased three times than normal value [6]. Hanje et al. (2006) 
reported and explained the cause of fulminant hepatic failure and 
death during DLX therapy [7]. Taking into all these considerations 
related to DLX inducing hepatotoxicity, the question arose whether 
DLX or its metabolites has any role in hepatotoxicity or not? It has been 
reported that DLX is metabolised by both CYP1A2 and CYP2D6. 
Therefore, the objective of this study was to evaluate the effect of 
Duloxetine or its metabolites on oxidative stress-induced hepatotoxicity. 
In order to further ascertain the oxidative stress-induced hepatotoxicity, 
docking studies were also performed accordingly. 
MATERIALS AND METHODS  
Materials 
Duloxetine (DLX; Batch Number: DL0040713) and Fluvoxamine 
(FLX; fig. 1B, Batch Number: LT-OFLM/014/12-13) were received 
from Indian companies namely Hetero Drugs Limited, Hyderabad, 
and Mehta API Pvt Ltd, Mumbai, respectively. Disodium 
ethylenediamine tetraacetic acid (EDTA), disodium hydrogen 
phosphate, potassium dihydrogen phosphate, sodium citrate and 
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trichloroacetic acid were purchased from SD Fine Chemicals, 
Mumbai, India. 5, 5´-dithiotris-2-nitro benzoic acid, tris buffer, 
sodium carbonate, glacial metaphosphoric acid, sodium potassium 
tartrate and sodium chloride were purchased from Loba Chemicals, 
New Delhi, India. Erythromycin stearate (ERY) was obtained from 
Himedia, Mumbai, India. All the solvents, reagents and chemicals 
were of analytical grades with 99% purity and in-house distilled 
water was used throughout the experiment. 
Docking studies 
Docking studies of DLX were performed using Argus lab, Pyrx 
virtual screening 0.8 and Autodock 4.0 along with Autodock vina. 
Before the docking study, we identified the active site domain 
using DogP active site recognize where the ligand has been shown 
the best configuration. Later, grid box was set according to 
previously recognised active site amino acid sequence. Finally, 
their binding affinity (kcal/mol) and counting of probable 
hydrogen bonds were evaluated. 
Animal grouping and experimental design  
Male Wistar rats (weighing 90-140 g) were purchased from Animal 
House, CSIR-CDRI, Lucknow, India (Approval No. UIP/IAEC/ 
2014/FEB./07) and were kept in polypropylene cages under 
standard conditions of temperature (25±1 °C) with 12 h light and 
dark conditions, diet and water ad libitum for 7 d. Animals were 
randomised and divided into following 5 groups having 6 animals in 
each group (n=6). Rats were kept fasted overnight before starting 
the experiment with free excess to water. Drugs were dissolved 
separately in distilled water as per the following treatment schedule. 
The first group served as normal control where animals were given 
only vehicle orally (1 ml/kg BW) for 21 d.  
The second group has been considered as hepatotoxic control, 
where ERY was given orally (100 mg/kg BW, served as 
hepatotoxicity control) for 14 d [8]. The remaining three groups 
have been considered as test groups where DLX, FLX and DLX+FLX 
were administered orally in doses of 10, 30 and 10+30 mg/kg body 
weight, respectively for 21 d [9, 10]. On 14th (for the hepatotoxic 
control group) and 21st days, blood samples were collected from 
retro-orbital plexus and centrifuged to separate plasma and kept at 
‒20 °C for further biochemical estimations. Rats from each group 
were sacrificed by cervical dislocation; livers were removed and 
kept in ‒20 °C for further biochemical estimation. 
Estimation of plasma ALT, AST and ALP 
Plasma ALT, AST [11] and ALP [12] were estimated according to the 
method as described earlier with slight modifications using specific 
assay kits obtained from Excel Diagnostics Pvt. Ltd., Hyderabad, India.  
Estimation of Tissue GSH, CAT, MDA, SOD, and PC 
Tissue GSH [13], CAT [14], MDA and SOD [15], and PC [16] levels 
were estimated as per the method reported earlier with or without 
slight modifications.  
Scanning electron microscopic (SEM) study of liver tissue 
Rat liver samples were mixed with 2.5% (v/v) of glutaraldehyde and 
were kept at 4 °C for 2-6 h. Then, the samples were washed with 0.1 
(M) phosphate buffer 3 times for 15 min interval. After that, 1% 
(w/v) osmium tetroxide was added to it and kept for 2 h at 4 °C and 
the samples were washed with 0.1 (M) phosphate buffer 3 times for 
15 min interval. Later, the specimens were dehydrated by using an 
increase in the percentage of drying (30%, 50%, 70%, 90%, 95%, 
and 100% v/v) to remove excess water from the samples at 4 °C for 
about 30 min period. After that, all specimens were dried in air and 
the critical point of drying was maintained at 31.5 °C and pressure at 
1100 psi. Finally, the samples were mounted onto the aluminium 
stubs with adhesive tape and observed the images using scanning 
electron microscope (JSM-6490LV. Jeol, Japan).  
Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 5.0 (Graph Pad 
Software, San Diago, CA). All results were expressed as mean±Standard 
deviation (SD). The data were analysed by one-way ANOVA (analysis of 
variances) followed by Bonferroni multiple comparison tests. For 
biochemical estimations, statistical significance differences were 
considered with respect to control group (aP<0.05, bP<0.01, cP<0.001).  
RESULTS 
Docking studies 
Docking images of DLX along with two target enzymes has been 
shown in fig. 2. DLX exhibited good binding affinity with CYP1A2 
enzyme (value-10.2 kcal/mol and one H-bond) whereas lower 
binding affinity was observed in the case of CYP2D6 (value-7.5 
kcal/mol and no H-bond) (table 1). 
  
Table 1: Binding affinities of DLX with human CYP1A2 AND CYP2D6. Comparatively, studies were performed by using various 























Fig. 2: Docking images of (A) DLX with human CYP1A2 (2HI4) and (B) DLX with human CYP2D6 (2F9Q). The round mesh circular showed 
the binding affinity of ligand with amino acids involved in binding poses 
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Plasma ALT, AST and ALP 
ALT level was slightly higher in DLX (~ 57 U/ml) treated group than 
normal control group (~ 40 U/ml) as shown in table 2. ALT (~ 37 
and 32 U/ml) level in plasma was found to be decreased in both FLX 
and DLX+FLX treated groups. ERY acted as a hepatotoxic control, 
which demonstrated the higher concentration of ALT in plasma. 
There was a significant increase in plasma AST level in both ERY 
(~182 U/ml) and DLX treated groups (~174 U/ml). AST level (~150 
U/ml) was closer to normal control after FLX and DLX+FLX treated 
groups. A similar result of plasma concentration of ALP was higher 
in both ERY and DLX treated groups. FLX and DLX+FLX treated 
groups also showed the similar higher concentration of plasma ALP 
in compared to normal control (table 2). 
  
Table 2: Various enzyme concentrations in plasma 
Groups ALT (U/ml) AST (U/ml) ALP (U/ml) 
Control 40.10±2.71 150.00±7.62 830.53±8.98 
ERY 56.37±1.42 182.37±8.01 956.93±4.55 
DLX 57.23±2.39a 174.2±7.82a 914.67±6.88b 
FLX 37.5±1.98 143.5±7.95 820.33±9.53 
DLX+FLX 32.6±2.82a 147.83±8.06 780.95±1.18 
Data were presented as mean±SD (n=6). Statistically, significant differences were observed between control and test groups [one way-ANOVA 
followed by Bonferroni multiple comparison test; (a<0.001, b<0.01)] 
 
Biochemical estimations in liver tissues 
In order to understand the mechanism of hepatotoxicity of DLX in 
Wistar rats, various oxidative stress-related parameters like GSH, 
MDA, SOD, CAT and PC in liver tissues were measured. As depicted 
in table 3, it was observed that GSH level was found to be decreased 
in DLX treated group. DLX and DLX+FLX treated groups also showed 
no toxic effect because of similar concentrations of biochemical 
parameters as in normal control. The level of MDA was higher in 
both ERY and DLX treated groups (~ 2.0 nM/mg of protein) as 
shown in table 3. This concentration again normalised for FLX and 
DLX+FLX treated groups. Similar trends were also observed for PC 
assay where the formation of PC was higher in ERY and DLX treated 
groups (table 3). In order to determine the oxidative stress-based 
hepatotoxicity, CAT and SOD enzyme level was measured separately. 
CAT is most abundant in the liver, which is mainly responsible for 
the catalytic decomposition of H2O2. Increase in concentration of 
H2O2 in DLX treated group depicted that there was less amount of 
CAT enzyme available in the tissues to decompose H2O2 (table 3). It 
was observed that SOD enzyme level was also decreased in DLX 
treated group in compared to normal control, FLX and DLX+FLX 
treated groups. 
  
Table 3: Various oxidative stress parameters in liver 
Groups 
 
SOD (U/mg of 
Protein) 
CAT (nM H2O2 decomposed/min/mg 
of protein ) 
GSH (µM/mg of 
Protein) 
TBARS  
(nM of MDA/mg of protein) 
PC (µg/mg of 
protein) 
Control 2.23±0.13 75.20±4.51 60.67±3.64 1.79±0.29 0.41±0.03 
ERY 1.11±0.06 58.33±5.50 42.15±2.52 5.36±0.22 0.69±0.04 
DLX 1.17±0.07a 97.88±5.87a 37.80±2.96a 5.12±0.20a 0.65±0.05a 
FLX 2.17±0.18 70.87±5.39 63.01±2.68 1.41±0.20 0.41±0.03 
DLX+FLX 1.80±0.10a 34.24±4.05a 60.46±4.82 2.43±0.14a 0.42±0.02 
Data represented as mean±SD (n=6). Statistically, significant differences were observed between control and test groups [one way-ANOVA followed 
by Bonferroni multiple comparison test; ap<0.001] 
 
SEM analysis of liver  
SEM analysis showed the presence of lesions in DLX treated group, 
whereas, it was absent in both FLX and DLX+FLX treated groups (fig. 3).  
 
 
Fig. 3: SWM photomicrographs of the liver tissues (A) Control, 
(B) ERY, (C) DLX, (D) FLX and (E) DLX+FLX. Tissue necrosis was 
observed in ERY and DLX treated rats which were less 
prominent in both FLX and DLX+FLX treated rats 
DISCUSSION  
Most of the hepatotoxic drugs are generally involved in increasing 
levels of liver enzymes and GSH level due to oxidative stress induced 
by some specific drugs, whereas some other drugs may take part in 
the alteration of liver mitochondrial functions and expression of 
liver genes [17-19]. Mechanism of oxidative stress also plays an 
important role in causing hepatotoxicity produced by some drugs 
like acetaminophen [20]. It is assumed that some orally 
administered drugs are involved in the generation of free radicals 
which may further elevate the tissue TBARS, PC and may reduce the 
CAT, GSH and SOD levels in liver, and increased level of plasma ALT, 
AST and ALP were collectively responsible for liver damages.  
Orally active DLX was metabolised by CYP1A2 to corresponding 
hydroxylated and epoxide metabolites which had a tendency to bind 
with GSH [1, 2]. This practical data was also confirmed by docking 
studies where we found that CYP1A2 was the major enzyme for DLX 
metabolism (fig. 2 and table 1). Taking into consideration of above 
observations, it was questionable whether parent DLX is hepatotoxic 
or its metabolites. To get the actual answer, metabolism of DLX 
using FLX (CYP1A2 inhibitor) was conducted, and various 
biochemical parameters were evaluated. 
Our results collectively suggested that all the enzyme levels were 
higher for DLX treated groups than control group whereas this level is 
slightly lower for both FLX and DLX+FLX treated groups as shown in 
table 2. Both AST and ALT are the liver enzymes which is responsible 
for transamination of amino acids, whereas ALP is responsible for 
catalysis of organic phosphate esters. These are the key enzymes of 
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liver, which are extracted out during liver damages [16, 21]. The 
increase of these enzymes in plasma during DLX treatment indicated 
the hepatic damage, which was further improved by FLX treatment. 
This was an indirect indication of liver damage, but it could not be 
explained how DLX produced toxicity in the liver after oral 
administration.  
The DLX treated rats depleted more reduced glutathione (GSH) than 
FLX and DLX+FLX treated groups (table 3). GSH is a tripeptide, which 
is most abundant in all tissues including liver. GSH has a major role in 
oxidation-reduction process, resulting in the formation of disulfide 
glutathione (GSSG) [22] during oxidative damage. Reduction of GSH 
level by DLX is an indication of oxidative stress-induced liver damage, 
which was improved during FLX treatment. The decrease in the levels 
of GSH in DLX treated rats represented the higher utilisation of GSH 
during oxidative damage which was completely restored during a 
single dose of FLX and combined dose of FLX with DLX.  
To prove the oxidative stress induced hepatotoxicity, the tissue MDA 
levels were also performed. Oxidation of lipids is another important 
parameter to measure the oxidative stress in living body [17]. From 
the result; it was observed that tissue MDA level was higher for DLX 
treated group, which was again restored to a normal level during 
FLX, and DLX+FLX treated rats (table 3). The Higher amount of MDA 
formation during DLX treatment was directly represented the 
oxidative damage of liver cells. Thus, the results indicated that DLX 
might be responsible for hepatotoxicity due to oxidative damages. 
In order to understand the relationship between oxidative stress and 
hepatotoxicity, PC assay was performed where a higher amount of PC 
was formed than DLX treated groups (table 3). The carboxyl group of 
protein become oxidised due to the formation of reactive oxygen 
species [23] and converted to PC, which is an important marker for 
oxidative stress. As depicted in table 3, DLX treated groups formed 
more PC than FLX and DLX+FLX treated groups which were an 
important indication of oxidative stress-induced liver damages. 
In order to further understand the mechanism of oxidative stress, both 
CAT and SOD enzyme levels in liver were measured. The enzyme CAT is 
also most abundant in the liver which catalyses the conversion of H2O2 to 
corresponding oxygen and water. The action of this enzyme is reduced 
due to the presence of peroxides and reactive oxygen species [24, 25]. 
H2O2 levels were measured, and values were compared between various 
treated groups. Increase in concentration of H2O2 in DLX treated sample 
depicted that there were less amount of CAT enzyme available in the 
tissue to decompose the H2O2 with respect to control and other treated 
groups (table 3). This assay indirectly indicated that oral administration 
of DLX reduced the level of CAT enzyme in the liver. Separately, the 
estimation of SOD levels in liver was performed. The SOD levels were 
also decreased in DLX treated groups, but the level of this enzyme 
became normal in FLX and DLX+FLX treated rats (table 3).  
For direct evidence of liver damages, SEM analyses of liver tissues were 
performed (fig. 3) and damages of liver tissues were observed in DLX 
treated rats which were absent in FLX, and DLX+FLX treated groups. 
CONCLUSION 
The hepatotoxicity of DLX might be due to oxidative stress produced by 
hydroxylated and epoxide metabolites, which may release free radicals 
or reactive oxygen species. Further studies in this context, such as 
preparation of hydroxylated and epoxide metabolites and measurement 
of their hepatotoxic potential are beyond the scope of this study.  
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